NCT04846530Unknown不适用
A Prospective, Single Blind, Single-center Study Evaluating the Histology and Intradermal Implantation of the Teosyal RHA® Collection of Fillers
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Biopsy specimens
研究概览
简要总结
The Teosyal RHA® family of products (RHA® 1, RHA® 2, RHA® 3, and RHA® 4) is approved in Canada for the correction of facial wrinkles and folds. In this study, the approved products will be placed in small boluses (0.2 mL) intradermally to allow for punch biopsies of the post-auricular space to be taken. The biopsies will include the injected material and surrounding skin tissue. Biopsies will be taken immediately after implantation of the product and at Day 30 and assessed by an independent blinded pathologist.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Crossover
- 时间视角
- Prospective
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Outpatient, male or non-pregnant, non-nursing females, at least 22 years of age, and in good general health.
- •Subject willing to abstain from other aesthetic procedures on the head or face including receiving other dermal fillers, laser treatments, use of any product that affects skin remodeling, or a product that may cause an active dermal response in the treatment area from screening through the last study follow-up visit.
- •Female subjects of childbearing potential must have a negative urine pregnancy test result at the Treatment Visit, prior to product administration.
- •Able to understand the requirements of the trial and sign informed consent including authorization to release health information.
- •Subject willing and able to comply with study follow-up procedures and schedule.
- •Subject willing to provide written informed consent for their participation in the study including authorization to release health information.
排除标准
- •Subject is a female of childbearing potential (e.g., not postmenopausal for at least one year or has not had a hysterectomy or tubal ligation) not using medically effective birth control (e.g., hormonal methods such as birth control pills; implants; Intrauterine Device (IUDs), etc., in use at least 30 days prior to injection or barrier methods such as condom and spermicide in use at least 14 days prior to injection), or is pregnant, lactating, or plans to become pregnant during the study.
- •Subject has participated in a clinical study in which an investigational device or drug was received in the 30 days prior to screening or plans to enroll in such a study during the course of the current study.
- •Subject is an employee or direct relative of an employee of the investigational site or Sponsor.
- •Subject has a serious or progressive disease, which, in the investigator's judgment, puts the subject at undue risk (e.g., uncontrolled diabetes, autoimmune pathology, cardiac pathologies).
- •Subject has a local acute inflammatory process or infection, or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of adverse events.
- •Subject has a disorder that may impact wound healing such as connective tissue or immunosuppressive disorder.
- •Subject has had an active skin disease in the treatment area within the past 6 months.
- •Subject has scars, infection, rosacea, herpes, acne, blotches or other pathology behind the ears. Subject is predisposed to keloidosis or hypertrophic scarring.
- •Subject has known allergy to hyaluronic acid, 1,4-butanediol diglycidyl ether (BDDE), gram-positive bacterial proteins or streptococcal proteins.
- •Subject has history of hypersensitivity to local anesthetics of the amide type, such as lidocaine.
- •Subject has severe allergies as manifested by a history of anaphylaxis, or a history or presence of multiple severe allergies.
- •Subject has a known bleeding disorder.
- •Subject has received or plans to receive within 1 week prior to injection through 1 week following or in the one week prior to 30 day biopsy through 1 week after any treatment/procedure that may impact coagulation such as high-dose Vitamin E, aspirin, anti-inflammatories, antiplatelets, thrombolytics, or any other medication that could increase the risk of bleeding. Subject has received within the past 3 months or plans to receive during the study chemotherapy agents, immunosuppressive medications, or systemic corticosteroids (inhaled steroids are acceptable).
- •Subject has received within the past 12 months or plans to receive during the study any treatment or procedure involving the post-auricular area.
- •Any condition or situation which, in the Investigator's opinion, puts the subject at significant risk, could confound the trial results, or may interfere significantly with the subject's participation in the trial.
结局指标
主要结局
Biopsy specimens
时间窗: Day 1
The biopsy specimens will be submitted to an independent laboratory for histological examination.
次要结局
- Biopsy specimens(Day 30)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Evaluating the Efficacy and Safety of Treatment With LinearFirm(ULTRAcel Q+) in Temporary Eyebrow LiftingHigh Intensity Focused UltrasoundNCT06457607Jeisys Medical Inc38
Unknown
不适用
CANadian Clinical Evaluation of SpiderFlash Arrhythmia DETECTion in SpiderFlash™ DeviceArrhythmias, CardiacNCT01218763Sorin Group Canada101
已完成
不适用
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent RegimenPsoriasisNCT04149587Bausch Health Americas, Inc.252
Unknown
1 期
A Trial of SHR-A1904 in Patients With Advanced Pancreatic CancerAdvanced Pancreatic CancerNCT04928625Shanghai Hengrui Pharmaceutical Co., Ltd.75
进行中（未招募）
1 期
A Study of SHR-A1904 in Patients With Advanced Solid CancerAdvanced Solid CancerNCT04877717Shanghai Hengrui Pharmaceutical Co., Ltd.107